Last update:

Clinical pharmacology news

New drug could slow the development of Alzheimer's

"Compound 10" is how Ursula Quitterer refers to the chemical compound that her team has developed and that could slow the progression of Alzheimer's disease. Quitterer is a professor of molecular pharmacology at ETH Zurich ...

New GLP-1 oral pill lowers blood sugar and reduces bodyweight, clinical trial finds

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight. At the American Diabetes Association's Scientific Session, Mass General Brigham physician investigator ...

Hay fever, antihistamines and the evidence on dementia risk

For millions of people around the world, pollen season means weeks of sneezing, itchy eyes, and a blocked or runny nose. The timing varies depending on where you live and which plants are in flower, but grass pollen is one ...

Africa races for Ebola vaccine as outbreak outpaces response

Researchers racing to develop a vaccine to fight the growing Ebola outbreak centered in the Democratic Republic of the Congo (DRC) say doses could be ready for human testing within "two to three months," while the more promising ...

Flu drugs show promise against cognitive decline

A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and ...

Koala vaccine offers clues to solving human health challenge

A vaccine first developed to protect koalas from a devastating disease is now offering rare insights that could help accelerate human vaccine development for one of the world's most common sexually transmitted infections.

Digital twin can reveal alcohol consumption in crime cases

Using a so-called digital twin, it is possible to predict with greater precision than at present how much alcohol a person has consumed and at what time. The study was conducted by researchers at Linköping University and ...

Study identifies new treatment targets for vascular dementia

A new study led by researchers at UNSW Sydney's Center for Healthy Brain Aging (CHeBA) has identified potential biological targets that could help guide future research into treatments for vascular dementia—a common and serious ...

TBI survivors turn to psychedelics for symptom relief

A new study from the University of Victoria (UVic) has identified a segment of traumatic brain injury survivors who are using psychedelics to self-medicate for cognitive, mood and somatic symptoms such as headaches. In a ...

Semaglutide improves vascular responsiveness to insulin

Glucagon-like peptide-1 receptor agonists, known as GLP-1 drugs, are highly effective at helping people lose weight and substantially lower the risk of heart attacks, strokes, and death from heart disease. A new study conducted ...

Weight-loss drugs could tackle Alzheimer's—study

A new study has found comprehensive evidence that "weight-loss" GLP-1 receptor agonists such as semaglutide are effective in tackling the biological drivers of Alzheimer's disease. The study, published in the journal Molecular ...